L-Asparagine, L-asparaginyl-L-asparaginyl- | 69356-48-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: L-Asparagine, L-asparaginyl-L-asparaginyl-
• 英文别名: (2S)-4-amino-2-[[(2S)-4-amino-2-[[(2S)-2,4-diamino-4-oxobutanoyl]amino]-4-oxobutanoyl]amino]-4-oxobutanoic acid
• CAS: 69356-48-5
• 化学式: C₁₂H₂₀N₆O₇
• 分子量: 360.32
• InChiKey: ACRYGQFHAQHDSF-ZLUOBGJFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -8.1
• 重原子数：
  25
• 可旋转键数：
  11
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  251
• 氢给体数：
  7
• 氢受体数：
  8

文献信息

• Intranasal administration of glucose-regulating peptides
  申请人：Quay C. Steven

  公开号：US20050143303A1

  公开（公告）日：2005-06-30

  Pharmaceutical compositions and methods are described comprising at least one glucose-regulating peptide, such as amylin, glucagon-like peptide-1 (GLP), pramlintide or exendin-4 and one or more mucosal delivery-enhancing agents for enhanced nasal mucosal delivery of the amylin, for treating a variety of diseases and conditions in mammalian subjects, including obesity and diabetes mellitus.

  本文介绍了一种药物组合和方法，其中包括至少一种调节葡萄糖的肽类，如降淀粉样肽、胰高血糖素样肽-1（GLP）、普拉林肽或外肽-4，以及一种或多种黏膜传递增强剂，以增强降淀粉样肽在鼻黏膜上的传递，用于治疗哺乳动物主体中的多种疾病和病况，包括肥胖和糖尿病。
• [EN] PHARMACEUTICAL FORMULATIONS FOR THE DELIVERY OF DRUGS HAVING LOW AQUEOUS SOLUBILITY<br/>[FR] FORMULATIONS PHARMACEUTIQUES POUR L'ADMINISTRATION DE MEDICAMENTS AYANT UNE FAIBLE SOLUBILITE AQUEUSE
  申请人：IMARX THERAPEUTICS INC

  公开号：WO2001049268A1

  公开（公告）日：2001-07-12

  Pharmaceutical formulations are provided that increase the systemic bioavailability of a drug that has low aqueous solubility. The drug is physically entrapped by a spatially stabilized matrix of a hydrophilic polymer, but is not covalently bound thereto. Phospholipid moieties are optionally conjugated to the hydrophilic polymer, and free phospholipids, stabilizing agents and/or other excipients may be incorporated into the formulations as well. Therapeutic methods are also provided, wherein a formulation of the invention is administered to a patient to treat a condition, disorder or disease that is responsive to a particular drug. Generally, administration is oral or parenteral.

  提供了一种制药配方，该配方可以增加水溶性低的药物的系统生物利用度。该药物被一个亲水性聚合物的空间稳定的基质物理捕获，但并未与之共价结合。磷脂酰基团可以选择性地与亲水性聚合物结合，而自由磷脂、稳定剂和/或其他辅料也可以被纳入到配方中。还提供了治疗方法，其中将发明的配方用于治疗对特定药物有反应的病症、疾病或疾病。一般来说，给药是口服或注射。
• PROTEIN CRYSTAL OF HUMAN CYTOCHROME P450 AROMATASE AND USES THEREOF
  申请人：GHOSH Debashis

  公开号：US20100197514A1

  公开（公告）日：2010-08-05

  The present invention relates to a protein crystal of at least one binding site of a human aromatase. The present invention also relates to a fully processed human cytochrome P450 aromatase and a protein crystal thereof. The present invention further relates to methods of making and using the aromatase and the protein crystal thereof.

  本发明涉及人类芳香化酶至少一个结合位点的蛋白晶体。本发明还涉及完全加工的人类细胞色素P450芳香化酶及其蛋白晶体。本发明还涉及制备和使用芳香化酶及其蛋白晶体的方法。
• PROTEIN CRYSTAL OF HUMAN CYTOCHROME P450 AROMATASE AND USES THEREOF
  申请人：GHOSH Debashis

  公开号：US20090204378A1

  公开（公告）日：2009-08-13

  The present invention relates to a protein crystal of at least one binding site of a human aromatase. The present invention also relates to a fully processed human cytochrome P450 aromatase and a protein crystal thereof. The present invention further relates to methods of making and using the aromatase and the protein crystal thereof.

  本发明涉及人类芳香化酶至少一个结合位点的蛋白晶体。本发明还涉及完全加工的人类细胞色素P450芳香化酶及其蛋白晶体。本发明还涉及制备和使用芳香化酶及其蛋白晶体的方法。
• Zea mays plants and transgenic zea mays plants regenerated from protoplasts or protoplast-derived cells
  申请人：CIBA-GEIGY AG

  公开号：EP0292435A1

  公开（公告）日：1988-11-23

  Methods of regenerating fertile Zea mays plants from protoplasts or protoplast-derived cells are described. The protoplasts or cells may be derived from embryogenic cell cultures or callus cultures. The protoplasts, cells and resulting plants may be transgenic, containing, for example, chimeric genes coding for a polypeptide having substantially the insect toxicity properties of the crystal protein produced by Bacillus thuringiensis.

  描述了从原生质体或原生质体衍生细胞再生可育玉米植株的方法。原生质体或细胞可以来自胚胎细胞培养物或胼胝体培养物。原生质体、细胞和产生的植物可以是转基因的，例如含有编码多肽的嵌合基因，这种多肽基本上具有苏云金芽孢杆菌产生的晶体蛋白的昆虫毒性特性。